Enanta Pharmaceuticals, Inc. (ENTA)
12.62
+0.74
(+6.23%)
USD |
NASDAQ |
Sep 28, 15:52
Enanta Pharmaceuticals Research and Development Expense (TTM) : 86.24M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 86.24M |
| March 31, 2026 | 91.32M |
| December 31, 2025 | 99.94M |
| September 30, 2025 | 106.74M |
| June 30, 2025 | 113.71M |
| March 31, 2025 | 115.24M |
| December 31, 2024 | 122.76M |
| September 30, 2024 | 131.48M |
| June 30, 2024 | 136.86M |
| March 31, 2024 | 151.11M |
| December 31, 2023 | 158.99M |
| September 30, 2023 | 163.52M |
| June 30, 2023 | 162.15M |
| March 31, 2023 | 158.26M |
| December 31, 2022 | 156.88M |
| September 30, 2022 | 164.52M |
| June 30, 2022 | 178.67M |
| March 31, 2022 | 186.58M |
| December 31, 2021 | 186.00M |
| September 30, 2021 | 174.11M |
| June 30, 2021 | 161.85M |
| March 31, 2021 | 149.54M |
| December 31, 2020 | 140.64M |
| September 30, 2020 | 136.76M |
| June 30, 2020 | 138.79M |
| Date | Value |
|---|---|
| March 31, 2020 | 138.57M |
| December 31, 2019 | 140.11M |
| September 30, 2019 | 142.21M |
| June 30, 2019 | 130.42M |
| March 31, 2019 | 124.44M |
| December 31, 2018 | 111.77M |
| September 30, 2018 | 94.86M |
| June 30, 2018 | 84.45M |
| March 31, 2018 | 71.37M |
| December 31, 2017 | 62.89M |
| September 30, 2017 | 57.45M |
| June 30, 2017 | 52.44M |
| March 31, 2017 | 47.82M |
| December 31, 2016 | 43.95M |
| September 30, 2016 | 40.46M |
| June 30, 2016 | 36.01M |
| March 31, 2016 | 31.48M |
| December 31, 2015 | 27.70M |
| September 30, 2015 | 23.19M |
| June 30, 2015 | 21.34M |
| March 31, 2015 | 19.64M |
| December 31, 2014 | 19.00M |
| September 30, 2014 | 18.74M |
| June 30, 2014 | 17.84M |
| March 31, 2014 | 17.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Perspective Therapeutics, Inc. | 82.13M |
| Coherus Oncology, Inc. | 97.61M |
| BridgeBio Pharma, Inc. | 505.38M |
| RenovoRx, Inc. | 5.614M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |